These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20937127)

  • 1. Open-label add-on treatment trial of minocycline in fragile X syndrome.
    Paribello C; Tao L; Folino A; Berry-Kravis E; Tranfaglia M; Ethell IM; Ethell DW
    BMC Neurol; 2010 Oct; 10():91. PubMed ID: 20937127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.
    Berry-Kravis E; Sumis A; Hervey C; Nelson M; Porges SW; Weng N; Weiler IJ; Greenough WT
    J Dev Behav Pediatr; 2008 Aug; 29(4):293-302. PubMed ID: 18698192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
    Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
    J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial.
    Champigny C; Morin-Parent F; Bellehumeur-Lefebvre L; Çaku A; Lepage JF; Corbin F
    Front Psychiatry; 2021; 12():762967. PubMed ID: 35058813
    [No Abstract]   [Full Text] [Related]  

  • 5. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
    Bilousova TV; Dansie L; Ngo M; Aye J; Charles JR; Ethell DW; Ethell IM
    J Med Genet; 2009 Feb; 46(2):94-102. PubMed ID: 18835858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9.
    Toledo MA; Wen TH; Binder DK; Ethell IM; Razak KA
    Behav Brain Res; 2019 Oct; 372():112068. PubMed ID: 31271818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase.
    Siller SS; Broadie K
    Dis Model Mech; 2011 Sep; 4(5):673-85. PubMed ID: 21669931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.
    Leigh MJ; Nguyen DV; Mu Y; Winarni TI; Schneider A; Chechi T; Polussa J; Doucet P; Tassone F; Rivera SM; Hessl D; Hagerman RJ
    J Dev Behav Pediatr; 2013 Apr; 34(3):147-55. PubMed ID: 23572165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline.
    Dziembowska M; Pretto DI; Janusz A; Kaczmarek L; Leigh MJ; Gabriel N; Durbin-Johnson B; Hagerman RJ; Tassone F
    Am J Med Genet A; 2013 Aug; 161A(8):1897-903. PubMed ID: 23824974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.
    Dansie LE; Phommahaxay K; Okusanya AG; Uwadia J; Huang M; Rotschafer SE; Razak KA; Ethell DW; Ethell IM
    Neuroscience; 2013 Aug; 246():186-98. PubMed ID: 23660195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.
    Çaku A; Pellerin D; Bouvier P; Riou E; Corbin F
    Am J Med Genet A; 2014 Nov; 164A(11):2834-42. PubMed ID: 25258112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of the psychiatric problems associated with fragile X syndrome.
    Hagerman RJ; Polussa J
    Curr Opin Psychiatry; 2015 Mar; 28(2):107-12. PubMed ID: 25602250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of metformin in fragile X syndrome: An open-label study.
    Proteau-Lemieux M; Lacroix A; Galarneau L; Corbin F; Lepage JF; Çaku A
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110307. PubMed ID: 33757860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).
    Berry-Kravis E; Hagerman R; Budimirovic D; Erickson C; Heussler H; Tartaglia N; Cohen J; Tassone F; Dobbins T; Merikle E; Sebree T; Tich N; Palumbo JM; O'Quinn S
    J Neurodev Disord; 2022 Nov; 14(1):56. PubMed ID: 36434514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial.
    de Diego-Otero Y; Calvo-Medina R; Quintero-Navarro C; Sánchez-Salido L; García-Guirado F; del Arco-Herrera I; Fernández-Carvajal I; Ferrando-Lucas T; Caballero-Andaluz R; Pérez-Costillas L
    Trials; 2014 Sep; 15():345. PubMed ID: 25187257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.
    Lovelace JW; Wen TH; Reinhard S; Hsu MS; Sidhu H; Ethell IM; Binder DK; Razak KA
    Neurobiol Dis; 2016 May; 89():126-35. PubMed ID: 26850918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BDNF in fragile X syndrome.
    Castrén ML; Castrén E
    Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.
    Siller SS; Broadie K
    Neural Plast; 2012; 2012():124548. PubMed ID: 22685676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective open-label study of aripiprazole in fragile X syndrome.
    Erickson CA; Stigler KA; Wink LK; Mullett JE; Kohn A; Posey DJ; McDougle CJ
    Psychopharmacology (Berl); 2011 Jul; 216(1):85-90. PubMed ID: 21318565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arbaclofen in fragile X syndrome: results of phase 3 trials.
    Berry-Kravis E; Hagerman R; Visootsak J; Budimirovic D; Kaufmann WE; Cherubini M; Zarevics P; Walton-Bowen K; Wang P; Bear MF; Carpenter RL
    J Neurodev Disord; 2017; 9():3. PubMed ID: 28616094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.